People · Operator
Named in public records as an officer, director or promoter · active 2020–2024 · Pharma, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| iTeos Therapeutics, Inc. | — | Pharma | Series D+ | $125.4M | $4.4B | 2020 |
| ImmunoPrecise Antibodies Ltd. | — | Pharmaceuticals | Seed | $2.5M | $9.3M | 2024 |
Chris Buyse at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Chris Buyse on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Greg Smith | 1 | 17 |
| Ansbert Gadicke | 1 | 7 |
| Natasha Tsai | 1 | 6 |
| Kristin Taylor | 1 | 4 |
| Mitch Levine | 1 | 4 |
| Detlev Biniszkiewicz | 1 | 4 |
| Robert Burke | 1 | 3 |
| Thomas D'Orazio | 1 | 2 |
| David Hallal | 1 | 2 |
| James Kuo | 1 | 2 |
| Dirk Witters | 1 | 1 |
| Robert Beecroft | 1 | 1 |
| Guy Champagne | 1 | 1 |
| Dawn Wattie | 1 | 1 |
| Michel Detheux | 1 | 1 |
| Priyanka Belawat | 1 | 1 |
| Tim Van Hauwermeiren | 1 | 1 |
| Ilse Roodnik | 1 | 1 |
| Jonathan Skipper | 1 | 1 |
| Barry Springer | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.